Drug Database
IN

influenza vaccine

✓ Approved

LG Chem Ltd. · · Vaccine

What is influenza vaccine?

influenza vaccine is a vaccine developed by LG Chem Ltd.. It is approved for therapeutic indications via inhaled or injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyLG Chem Ltd.
Drug ClassVaccine, Large Molecules
Molecular Target, ,
RouteInhaled, Injectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, LG Chem Ltd.

Mechanism of Action

Molecular Targets

influenza vaccine acts on 3 molecular targets:

(M1)
(HA)
(neuraminidase, influenza A virus)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Related Research Articles

PubMedAdvances in virology2026-09-20

Comparative Sequence Analysis of the Envelope Gene of Kyasanur Forest Disease Virus Vaccine Strain With Currently Circulating Field Strains.

Kaje Keerthi K, Marinaik Chandranaik B CB, Gomes Amitha Reena AR, Rizwan Apsana A et al.

The present study was undertaken with the objective of performing comparative sequence analysis of the envelope (E) gene of Kyasanur forest disease virus (KFDV) vaccine strain P9605 with the circulating field strains. The study was taken up as the currently used KFDV vaccine strain, KFDV P9605, was isolated in the 1960s. For this study, we designed two sets of primers targeting the complete amplification of the E gene of KFDV. The sequencing was performed by the Sanger method, and the deduced sequence of the vaccine virus was deposited in GenBank with accession number PX067005. This sequence obtained for the vaccine virus was aligned and compared with sequences of GenBank-deposited circulating field strains. We also performed comparative sequence analysis of the Kyasanur forest disease (KFD) vaccine seed virus having passaged twice in mouse brain with the vaccine seed virus passaged six times in mouse brain to investigate whether multiple passages in mouse brain will lead to genetic mutation in the immunologically important E gene. The phylogenetic analysis revealed seven amino acid mutations in the field strains at positions A123T, S158N, D178E, D239N, A313S, M429I, and G479A when compared with the vaccine strain. We did not find any mutations at the critical fusogenic segment (residues 98-113) in the E gene of currently circulating field strains compared to the vaccine seed virus. The study found no genetic variations in the E gene of the KFD virus passed two times and passed six times in mouse brain. We performed SWISS-MODEL homology modeling, AlphaFold protein analysis, and Ramachandran plot analysis to study the E protein structures and stability. The observations made in this study suggest slow evolutionary drift and conserved structural stability of the envelope gene of KFDV ever since its emergence 7 decades ago; however, the functional implications of these amino acid substitutions need further studies on their roles in viral infectivity, transmission, and impact on immunity.

PMID 42763584
Read full article →
PubMedEMBO reports2026-09-20

TRIM62 facilitates influenza A virus entry by regulating WASH-dependent endosomal trafficking.

Gupta Kajal K, Pal Sampurna S, Tyagi Arpit A, Bajaj Roohani R et al.

Endocytosis enables efficient cargo uptake while restricting uncontrolled cellular entry, yet how this balance is enforced during endocytic uptake remains poorly understood. Using influenza A virus (IAV) as a model cargo, we reveal a previously unrecognized role for the pentameric WASH complex (WASH) as a regulatory hub that integrates both permissive and inhibitory functions to control viral endocytosis. While the WASH subunits WASH1, CCDC53, SWIP, and Strumpellin collectively promote IAV entry, the FAM21 subunit acts antagonistically. Our data suggest that FAM21-mediated association of WASH with the retromer subunit VPS35 restrains the pro-endocytic activity of WASH, thereby limiting viral uptake. This inhibitory FAM21-VPS35 axis is counteracted by the E3 ubiquitin ligase TRIM62, which maintains WASH in a retromer-free, endocytically competent state that facilitates viral internalization. Beyond IAV, the WASH1 subunit and VPS35 also exhibit opposing roles during cholera toxin B uptake, suggesting a broader function in lipid raft-mediated endocytosis. Together, our findings establish WASH as a key determinant of IAV endocytosis, with TRIM62 modulating retromer-mediated restriction to facilitate productive viral entry.

PMID 42763336
Read full article →
PubMedJournal of inflammation research2026-09-20

Dimethyl Sulfoxide Modulates T Cell-Mediated Immunity to Attenuate Influenza A Virus Infection.

Jeng Po-Hsuan PH, Tsai Meng-Wei MW, Huang Shing-Hwa SH, Huang Tien-Ru TR et al.

Influenza A virus (IAV) remains a major threat because vaccines provide limited cross-protection and antiviral resistance is rising. Dimethyl sulfoxide (DMSO) is immunomodulatory, but its effect on IAV has not been tested in vivo. We evaluated its efficacy and mechanism in a murine H1N1 model. Male C57BL/6 mice were intranasally challenged with an LD50 of A/Puerto Rico/8/1934 (H1N1) and given daily subcutaneous DMSO (0.22 g/kg/day) or phosphate-buffered saline (PBS) on days 1-7. Survival was monitored for 21 days; lung and bronchoalveolar lavage fluid (BALF) were collected on day 8. Lung histology (hematoxylin and eosin), BALF cytokines (sandwich ELISA), lung and splenic IFN-γ-producing CD4+ and CD8+ T cells (flow cytometry), and whole-lung RNA sequencing (differential expression, KEGG enrichment) were assessed. BALF viral burden was measured by neuraminidase activity assay and TCID50. In vitro, splenic CD8+ T cells exposed to 0%, 0.5%, or 1.0% DMSO were immunoblotted for lymphocyte-activation gene 3 (LAG3). DMSO significantly improved 21-day survival and attenuated alveolar inflammatory infiltration. Day-8 BALF viral titers were significantly lower with DMSO (mean 2.2×103 vs 4.3×104 TCID50/mL; p = 0.034), as was neuraminidase activity. BALF IFN-γ and TGF-β were elevated, whereas TNF-α, IL-6, and IL-1β were not. IFN-γ+ CD8+ T cells increased in the lung but not the spleen; CD4+ populations were unchanged. RNA sequencing showed enrichment of cytokine-cytokine receptor interaction and PI3K/Akt signaling and upregulation of T-box factors, PPAR-γ, and Nek kinases. In vitro, DMSO accelerated LAG3 induction in CD8+ T cells within 12-48 h. DMSO is associated with attenuated IAV severity, a lower day-8 airway viral burden, and a localized expansion of IFN-γ-producing CD8+ T cells, without a concomitant rise in the pro-inflammatory cytokines TNF-α, IL-6, or IL-1β. These associations are correlative and support further investigation of DMSO as a host-directed adjunct for influenza.

PMID 42763701
Read full article →
PubMedJournal of exposure science & environmental epidemiology2026-09-20

A dangerous combination: how co-occurring floods and blackouts increase cardiovascular hospitalizations.

Chen Yineng Y, Tangang Randy R, Sun Yanan Y, Zaloom Stephanie S et al.

Extreme weather events (EWEs) are becoming more frequent, but few have assessed the joint effects of floodings and power outages (POs) on health. We aimed to quantify the independent and joint effects of flooding and POs on hospitalizations for cardiovascular diseases (CVDs). Associations between flooding/POs and CVD hospitalizations in New York State (NYS) were estimated using distributed lag nonlinear models (DLNMs) within a quasi-Poisson regression framework, adjusting for PM2.5, weather factors and time-varying factors. We also evaluated length of stay, costs and comorbidities, thresholds, and compared the before and during COVID-19. Stratified analyses were conducted by CVD subtypes, demographics, season, and urbanicity. Flooding and POs were independently associated with total and specific CVDs, but the impact was stronger when they co-occurred (highest RR = 1.09, 95% CI: 1.03-1.15). CVD risk increased when flooding persisted for >3 days and when POs exceeded 15.3%. Flooding/POs were associated with longer hospital stays and higher comorbidities. Flooding/PO joint occurrence showed larger risk of CVD hospitalization during COVID-19, although not statistically significant. Stronger joint effects were observed on subtypes of hypertension, stroke, and ischemic heart disease, people over 65 years, those with Medicaid or no insurance coverage, rural residents, and during winter/spring. This study highlights the health impacts of co-occurring environmental hazards of flooding and POs, revealing seasonal and temporal patterns and identifying vulnerable subgroups. Targeting susceptible population and deploying preparedness efforts in critical time windows may help mitigate related excess CVD burden. Our study provides new evidence on the impact of co-occurring flooding and POs on CVD hospitalizations. We found that their joint occurring is associated with greater increases in CVD hospitalizations than either exposure alone, disproportionately affecting older adults, socioeconomically vulnerable populations, and rural communities. Distinct seasonal, temporal, and threshold patterns were identified for flooding and POs. These findings offer useful information for emergency management agencies to reduce CVD burden during compound hazard events.

PMID 42763347
Read full article →
PubMedClinical drug investigation2026-09-20

Symptomatic Interventions for Allergic Rhinitis Without Comorbid Asthma: A Dose-Stratified Network Meta-analysis.

Salimi Sajjad S, Hamidi Arezoo A, Babajani Mohammad Mahdi MM, Mohammadnejad Amirreza A et al.

Allergic rhinitis (AR) is a prevalent chronic condition with a substantial global burden. Although numerous therapeutic interventions exist, their comparative efficacy and safety remain unclear. The objective was to evaluate symptomatic interventions for seasonal and perennial AR without comorbid asthma via a systematic review and dose-stratified network meta-analysis (NMA). We systematically searched Web of Science, Cochrane Library, Scopus, PubMed, and Embase for randomized controlled trials. Studies evaluating immunotherapy, alternative medicine, or primarily enrolling patients with comorbid asthma were excluded. A frequentist random-effects NMA compared interventions at class and dose-specific levels. Primary outcomes were total nasal symptom score (TNSS), total ocular symptom score, quality of life, and adverse events. Treatment rankings were derived using the surface under the cumulative ranking curve (SUCRA), and the certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation for Network Meta-Analysis for the TNSS outcome. The protocol was registered in PROSPERO (CRD42024507281). Global and local inconsistencies were evaluated. From 36,669 records, 175 randomized controlled trials (RCTs) encompassing over 90,000 participants were included. In the network meta-analysis, treatment rankings varied across outcomes, and no single regimen consistently outperformed others; the observed heterogeneity and significant inconsistency in several networks precluded firm conclusions regarding comparative effectiveness. Intra-class differences in effect sizes were observed across several drug classes. Certain higher-dose intranasal corticosteroid monotherapies appeared among the top-ranked interventions in SUCRA analyses. Still, these rankings should be interpreted cautiously given the substantial heterogeneity and inconsistency in some networks. The certainty of evidence for the TNSS outcome was moderate to very low in most comparisons. Despite sensitivity analyses, significant statistical incoherence persisted in several comparisons, particularly for TNSS in seasonal AR. The analysis was limited to patients without comorbid asthma. Overall, no universally superior regimen could be identified. Given the remaining heterogeneity and inconsistency, the findings should be regarded as exploratory and hypothesis-generating rather than as definitive evidence of comparative effectiveness. These findings raise the possibility that treatment selection may benefit from an individualized approach, although confirmatory studies are needed. PROSPERO CRD42024507281.

PMID 42763361
Read full article →
PubMedEClinicalMedicine2026-09-19

Effectiveness of the 2025-2026 seasonal influenza vaccine among U.S. veterans: an observational study.

Xie Yan Y, Choi Taeyoung T, Al-Aly Ziyad Z

Annual vaccination is the primary strategy for preventing adverse clinical outcomes associated with seasonal influenza, but vaccine effectiveness varies by season with the degree of antigenic match and the predominant circulating subtype. The 2025-2026 season has been dominated by a newly emerged, antigenically distinct influenza A(H3N2) subclade K that arose after the vaccine strain was selected, raising concern about a vaccine mismatch and reduced effectiveness. Contemporary, season-specific evidence on effectiveness against clinically important outcomes is needed. We used U.S. Department of Veterans Affairs (VA) electronic health records to emulate a series of 24 sequential 7-day target trials among VA users with an in-person primary care visit between September 15, 2025, and February 28, 2026, comparing those who did and did not receive a seasonal influenza vaccine at the visit. The final analytic cohort comprised 1,401,492 participant-trials (526,350 vaccinated and 875,142 unvaccinated). Exposure was defined as receipt of the 2025-2026 seasonal influenza vaccine on the date of an eligible primary care visit, compared with no seasonal influenza vaccination at that visit or during follow-up. The primary outcome was a composite of seasonal influenza-associated emergency department visit or hospitalization. Individual components were also evaluated. Vaccine effectiveness (VE), defined as 1 minus the risk ratio, was estimated as the per-protocol effect among vaccinated participants using discrete-time survival models with inverse-probability-of-treatment and inverse-probability-of-censoring weighting. Marginal cumulative risks, and risk differences (RDs) per 10,000 persons, together with risk ratios, were estimated. Compared with no vaccination, receipt of the 2025-2026 vaccine was associated with a lower risk of the composite outcome (VE, 21.95%; 95% CI, 16.08%-27.65%; RD per 10,000 persons, -4.94; 95% CI, -6.49 to -3.47), influenza-associated emergency department visits (VE, 22.25%; 95% CI, 16.38%-27.94%; RD, -5.01; 95% CI, -6.55 to -3.53), and influenza-associated hospitalizations (VE, 31.84%; 95% CI, 14.77%-46.27%; RD, -1.08; 95% CI, -1.82 to -0.44). Vaccination was associated with lower risk of the composite outcome across prespecified subgroups defined by age (≤65 and >65 years) and immunocompromised status. Results were consistent across multiple sensitivity analyses, and negative outcome controls (all-cause hospitalization and all-cause death within 14 days) showed no association with vaccination. In analyses applying the same design to the 2024-2025 season, vaccine effectiveness was lower in 2025-2026 than in 2024-2025 for every outcome (composite, 21.95% vs 32.15%; approximately 30% lower in relative terms). The 2025-2026 seasonal influenza vaccine was associated with reductions in influenza-associated emergency department visits and hospitalizations, but its effectiveness was lower than in the immediately preceding season. These findings provide contemporary, season-specific evidence supporting the continued use of seasonal influenza vaccination to prevent clinically important influenza outcomes. U.S. Department of Veterans Affairs.

PMID 42761462
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about influenza vaccine